利妥昔单抗在原发性中枢神经系统淋巴瘤中的作用。
The Role of Rituximab in Primary Central Nervous System Lymphoma.
机构信息
Departments of Neuro-Oncology, Erasmus MC Cancer Center, Postbus 2040, 3000, CA, Rotterdam, The Netherlands.
Departments of Hematology, Erasmus MC Cancer Center, Postbus 2040, 3000, CA, Rotterdam, The Netherlands.
出版信息
Curr Oncol Rep. 2020 Jun 29;22(8):78. doi: 10.1007/s11912-020-00941-8.
Abstract
PURPOSE OF REVIEW
The treatment of primary central nervous system lymphoma (PCNSL) is still under debate. One of the issues is the role of rituximab in improving the outcome. Here, we summarize the existing evidence, and comment on the literature on this topic.
RECENT FINDINGS
Two randomized controlled studies have been published recently, with conflicting results. Although the evidence of the benefit of rituximab is limited, it is already incorporated into many treatment regimens, both in studies and in standard clinical practice. The use of rituximab in PCNSL is still a matter of debate. A positive effect on the outcome is uncertain. However, there are no clinical signs of significantly increased toxicity. The uncertain positive effect should therefore be weighed against the increased costs of the treatment.
摘要
目的综述
原发性中枢神经系统淋巴瘤（PCNSL）的治疗仍存在争议。其中一个问题是利妥昔单抗在改善预后方面的作用。在此，我们对该主题的现有证据进行总结和评论。
最近的发现
最近发表了两项随机对照研究，结果相互矛盾。尽管利妥昔单抗有益的证据有限，但它已经被纳入许多治疗方案中，包括研究和标准临床实践。利妥昔单抗在 PCNSL 中的应用仍存在争议。对结局的积极影响尚不确定。然而，并没有明显增加毒性的临床迹象。因此，不确定的积极影响应该与治疗费用的增加进行权衡。
相似文献
1
The Role of Rituximab in Primary Central Nervous System Lymphoma.利妥昔单抗在原发性中枢神经系统淋巴瘤中的作用。
Curr Oncol Rep. 2020 Jun 29;22(8):78. doi: 10.1007/s11912-020-00941-8.
2
Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysis.利妥昔单抗治疗原发性中枢神经系统淋巴瘤：系统评价和荟萃分析。
Hematol Oncol. 2019 Dec;37(5):548-557. doi: 10.1002/hon.2666. Epub 2019 Oct 9.
3
Effect of rituximab on primary central nervous system lymphoma: a meta-analysis.利妥昔单抗对原发性中枢神经系统淋巴瘤的影响：一项荟萃分析。
Int J Hematol. 2017 Nov;106(5):612-621. doi: 10.1007/s12185-017-2316-z. Epub 2017 Sep 12.
4
Review of rituximab in primary CNS lymphoma.利妥昔单抗治疗原发性中枢神经系统淋巴瘤的综述。
J Neurol Sci. 2020 Mar 15;410:116649. doi: 10.1016/j.jns.2019.116649. Epub 2019 Dec 25.
5
Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry.利妥昔单抗在原发性中枢神经系统淋巴瘤患者治疗中的作用：捷克淋巴瘤研究组登记处的回顾性分析
Leuk Lymphoma. 2016 Dec;57(12):2777-2783. doi: 10.3109/10428194.2016.1167203. Epub 2016 Apr 18.
6
Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.利妥昔单抗、甲氨蝶呤、丙卡巴肼、长春新碱及强化阿糖胞苷巩固治疗老年原发性中枢神经系统淋巴瘤（PCNSL）：一项LOC网络研究
J Neurooncol. 2017 Jun;133(2):315-320. doi: 10.1007/s11060-017-2435-7. Epub 2017 Apr 21.
7
[Outcomes of primary central nervous system lymphoma patients treated with high-dose methotrexate and rituximab].[接受大剂量甲氨蝶呤和利妥昔单抗治疗的原发性中枢神经系统淋巴瘤患者的治疗结果]
Rinsho Ketsueki. 2019;60(2):87-92. doi: 10.11406/rinketsu.60.87.
8
Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.甲氨蝶呤-阿糖胞苷-地塞米松联合化疗联合或不联合利妥昔单抗治疗原发性中枢神经系统淋巴瘤患者。
Oncotarget. 2017 Jul 25;8(30):49156-49164. doi: 10.18632/oncotarget.17101.
9
White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab.原发性中枢神经系统淋巴瘤患者在接受大剂量甲氨蝶呤联合或不联合利妥昔单抗治疗后的白质变化。
J Neurooncol. 2019 Dec;145(3):461-466. doi: 10.1007/s11060-019-03279-9. Epub 2019 Oct 16.
10
Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma.惰性中枢神经系统淋巴瘤患者脑室内注射利妥昔单抗后的脑脊液客观反应
CNS Oncol. 2015;4(3):131-5. doi: 10.2217/cns.15.3. Epub 2015 Apr 23.
引用本文的文献
1
A Single-Center Experience: Integrated Management in Primary Central Nervous System Lymphoma.单中心经验：原发性中枢神经系统淋巴瘤的综合管理
Cureus. 2024 Dec 3;16(12):e75022. doi: 10.7759/cureus.75022. eCollection 2024 Dec.
2
[Primary central nervous system lymphoma in immunocompetent patient: A case report].[免疫功能正常患者的原发性中枢神经系统淋巴瘤：一例报告]
Rev Med Inst Mex Seguro Soc. 2024 Jul 1;62(4):1-6. doi: 10.5281/zenodo.11397215.
3
Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance.序贯大剂量甲氨蝶呤和阿糖胞苷给药可改善原发性中枢神经系统淋巴瘤真实世界患者的预后：来自澳大拉西亚淋巴瘤联盟的报告
EJHaem. 2024 Jun 21;5(4):709-720. doi: 10.1002/jha2.951. eCollection 2024 Aug.
4
Correlation of functional magnetic resonance imaging features of primary central nervous system lymphoma with vasculogenic mimicry and reticular fibers.原发性中枢神经系统淋巴瘤的功能磁共振成像特征与血管生成拟态及网状纤维的相关性
Heliyon. 2024 May 29;10(11):e32111. doi: 10.1016/j.heliyon.2024.e32111. eCollection 2024 Jun 15.
5
Outcomes and relapse patterns in primary central nervous system lymphoma: Longitudinal analysis of 559 patients diagnosed from 1983 to 2020.原发性中枢神经系统淋巴瘤的结局和复发模式：1983 年至 2020 年诊断的 559 例患者的纵向分析。
Neuro Oncol. 2024 Nov 4;26(11):2061-2073. doi: 10.1093/neuonc/noae115.
6
First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study.初诊原发性中枢神经系统淋巴瘤患者接受大剂量甲氨蝶呤与替尼泊苷一线诱导化疗的效果比较：一项回顾性、多中心队列研究。
BMC Cancer. 2023 Aug 11;23(1):746. doi: 10.1186/s12885-023-11268-5.
7
Diagnosis and management of adult central nervous system leukemia.成人中枢神经系统白血病的诊断与管理
Blood Sci. 2023 May 30;5(3):141-149. doi: 10.1097/BS9.0000000000000162. eCollection 2023 Jul.
8
Immunochemotherapy or chemotherapy alone in primary central nervous system lymphoma: a National Cancer Database analysis.原发性中枢神经系统淋巴瘤采用免疫化疗还是单纯化疗：国家癌症数据库分析。
Blood Adv. 2023 Sep 26;7(18):5470-5479. doi: 10.1182/bloodadvances.2023010352.
9
A Systematic Review of High-Dose Methotrexate for Adults with Primary Central Nervous System Lymphoma.大剂量甲氨蝶呤治疗成人原发性中枢神经系统淋巴瘤的系统评价
Cancers (Basel). 2023 Feb 25;15(5):1459. doi: 10.3390/cancers15051459.
10
Rituximab with high-dose methotrexate is effective and cost-effective in newly diagnosed primary central nervous system lymphoma.利妥昔单抗联合大剂量甲氨蝶呤治疗新诊断原发性中枢神经系统淋巴瘤有效且具成本效益。
Sci Rep. 2022 Dec 13;12(1):21541. doi: 10.1038/s41598-022-24922-y.
本文引用的文献
1
White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab.原发性中枢神经系统淋巴瘤患者在接受大剂量甲氨蝶呤联合或不联合利妥昔单抗治疗后的白质变化。
J Neurooncol. 2019 Dec;145(3):461-466. doi: 10.1007/s11060-019-03279-9. Epub 2019 Oct 16.
2
Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysis.利妥昔单抗治疗原发性中枢神经系统淋巴瘤：系统评价和荟萃分析。
Hematol Oncol. 2019 Dec;37(5):548-557. doi: 10.1002/hon.2666. Epub 2019 Oct 9.
3
High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China.大剂量甲氨蝶呤联合替莫唑胺治疗未经治疗的原发性中枢神经系统淋巴瘤：来自中国的回顾性研究。
Cancer Med. 2019 Apr;8(4):1359-1367. doi: 10.1002/cam4.1906. Epub 2019 Mar 1.
4
Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study.原发中枢神经系统淋巴瘤患者年龄 60 岁及以下时采用放疗或自体造血干细胞移植治疗的结果：ANOCEF-GOELAMS 多中心随机Ⅱ期 PRECIS 研究结果。
J Clin Oncol. 2019 Apr 1;37(10):823-833. doi: 10.1200/JCO.18.00306. Epub 2019 Feb 20.
5
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.利妥昔单抗治疗原发性中枢神经系统淋巴瘤（HOVON 105/ALLG NHL 24 研究）：一项随机、开放标签、III 期分组研究。
Lancet Oncol. 2019 Feb;20(2):216-228. doi: 10.1016/S1470-2045(18)30747-2. Epub 2019 Jan 7.
6
Efficacy of the Nordic and the MSKCC chemotherapy protocols on the overall and progression-free survival in intracranial PCNSL.北欧和纪念斯隆凯特琳癌症中心（MSKCC）化疗方案对原发性中枢神经系统淋巴瘤（PCNSL）患者总生存期和无进展生存期的疗效。
Blood Cells Mol Dis. 2018 Nov;73:25-32. doi: 10.1016/j.bcmd.2018.08.005. Epub 2018 Aug 30.
7
Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial.福莫司汀、替尼泊苷和地塞米松与大剂量甲氨蝶呤加阿糖胞苷治疗新诊断的原发性中枢神经系统淋巴瘤的随机 2 期试验。
J Neurooncol. 2018 Nov;140(2):427-434. doi: 10.1007/s11060-018-2970-x. Epub 2018 Aug 14.
8
Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05).利妥昔单抗联合标准化疗用于原发性中枢神经系统淋巴瘤（PCNSL）的II期研究：一项东部肿瘤协作组（ECOG）-美国放射肿瘤学协作组（ACRIN）癌症研究组（E1F05）的试验
Oncotarget. 2017 Nov 6;9(1):766-773. doi: 10.18632/oncotarget.22332. eCollection 2018 Jan 2.
9
Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.甲氨蝶呤-阿糖胞苷-地塞米松联合化疗联合或不联合利妥昔单抗治疗原发性中枢神经系统淋巴瘤患者。
Oncotarget. 2017 Jul 25;8(30):49156-49164. doi: 10.18632/oncotarget.17101.
10
Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989-2015.仅70岁及以下原发性中枢神经系统淋巴瘤患者的生存率有所提高：一项基于荷兰1989 - 2015年发病率、初始治疗及生存情况的人群研究。
Leukemia. 2017 Aug;31(8):1822-1825. doi: 10.1038/leu.2017.128. Epub 2017 Apr 28.
Zotero 插件